Clinical Trial

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-26; most recent amendment 2025-07-27.
Trial Details
NCT Number NCT06484556
Lead Sponsor Tao Zhang
Collaborators: Neowise Biotechnology
Conditions Tumor, Solid
Enrollment 9 participants
Start Date 2024-06-19
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-31